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This paper provides an overview of the ethical issues in the international clustered 
regularly interspaced short palindromic repeats (CRISPR) genome editing debate from 
March 2015 to September 2016. We present the regulatory framework for embryo 
research in the UK, and explain why CRISPR is not a significant break with the past. 
We discuss the ethical issues arising from CRISPR applications beyond human embryos, 
namely the use of gene drive-engineered mosquitoes to eradicate diseases, engineering 
nonhuman animals to harvest organs for human transplant and engineering crops. We 
discuss the experiments that have demonstrated the technical feasibility of cultivating 
embryos in vitro for up to 14 days, and possibly beyond this limit, and the ethical issues 
arising from the proposal to extend the limit beyond 14 days.
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First applied in mammalian cells in 2013, 
the CRISPR/Cas9-targeted genome-editing 
tool is an RNA-guided tool that consists of 
naturally occurring clustered regularly inter-
spaced short palindromic repeats (CRISPR) 
and CRISPR-associated (Cas) nucleases 
(enzymes), which can generate DNA double-
strand breaks at high efficiency to disrupt 
genes and insert desired DNA sequences. 
CRISPR/Cas9 is not the only existing 
genome-editing technique, but has advan-
tages over others for its efficiency (lower 
number of off-target effects), versatility 
(the system works in all eukaryotic organ-
isms) and accuracy (as it enables targeted 
editing). The total cost of the technique is 
as little as US$30, in what has been referred 
to as ‘democratization’ of the gene-editing 
technology [1]. The system is now ubiqui-
tously used in biology laboratories world-
wide for a variety of purposes and routine 
genetic modifications [2,3]. In this paper we 
will be referring to CRISPR technology as 
different nucleases can be associated with 
the repeats, although Cas9 is the one – thus 
far – predominantly used.
In the ‘CRISPR applications on human 
embryos: big ado about nothing?’ section, 
we introduce the applications on human 
embryos and the debate that has ensued 
internationally. In the section ‘CRISPR & 
the regulation of embryo research in the 
UK: not a significant break with the past’ 
we describe the regulatory framework for 
research on human embryos in the UK and 
explain how CRISPR technology is posi-
tioned within this legal and ethical context. 
In section ‘Which CRISPR futures? CRISPR 
applications beyond the human embryo’ we 
outline areas of ethical concern of CRISPR 
applications beyond human embryos, namely 
engineering mosquitoes to eradicate diseases; 
engineering nonhuman animals for human 
organ transplant; and engineering crops for 
human consumption. In section ‘CRISPR 
embryo debate: momentum building outside 
the USA?’ we present some recent interna-
tional developments of the debate on CRISPR 
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applications on human embryos, and discuss the recent 
experiments demonstrating the feasibility to cultivate 
embryos in vitro for longer than the current limit of 
14 days. In the last section of the paper we reflect on 
some possible ‘CRISPR futures’ and we conclude reit-
erating the importance of considering the non-human 
applications of the technology.
CRISPR applications on human embryos: big 
ado about nothing?
The beginning of the CRISPR debate can be traced 
back to March/April 2015 and to the publication in the 
journal, Protein & Cell, by a group of Chinese scien-
tists led by Huang of the first findings resulting from 
the application of CRISPR in nonviable (tripronuclear 
zygotes) human embryos [4]. Aware of the forthcom-
ing publication by Chinese scientists, a group of US 
scientists led by Jennifer Doudna at UC Berkeley (one 
of the co-discoverers of CRISPR mechanisms, with 
Emmanuelle Charpentier at Humboldt University in 
Germany in the same team, and in the other team Fen 
Zhang at The Broad Institute, MIT) published a letter 
on 3 April 2015 to the journal, Science, recommend-
ing a ‘prudent pathway’ for genomic engineering and 
germline gene modification. The letter called for a self-
imposed temporary moratorium on germline applica-
tions of CRISPR-Cas9 until further deliberation [5]. 
This call was reminiscent of the self-imposed tempo-
rary moratorium on recombinant DNA technologies 
of the Asilomar conference in 1975 (indeed, the par-
allels were explicit as Nobel prize winners, Paul Berg 
and David Baltimore, were two of the authors and the 
organizers of the Asilomar conference) [6]. D Baltimore 
and colleagues were not the only ones calling for pru-
dency, other scientists from the Alliance for Regenera-
tive Medicine in Washington, DC, USA led by Edward 
Lanphier (chairman of the Alliance) wrote a letter 
striking similar chords to the journal Nature, which is 
aptly titled, ‘Don’t edit the human germline’ [7].
At the end of April 2015, the Director of the NIH, 
Dr Francis Collins, released a statement affirming that 
the NIH would not fund any use of gene-editing tech-
nologies on human embryos. The motivation was that 
“the concept of altering the human germline in embryos 
for clinical purposes has been debated over many 
years from many different perspectives, and has been 
viewed almost universally as a line that ‘should not be 
crossed’” [8]. Eric Lander, Director of the Broad Institute 
at MIT (to note – Fen Zhang, one of the inventors of the 
technology, is based at the Broad Institute at the MIT 
and working with George Church). echoed in the New 
England Journal of Medicine (under the not-particularly 
original heading of, ‘Brave New Genome’ of a need for 
‘caution’ against ‘reckless’ applications and quotes a sup-
posed ‘long-standing consensus’) that the human germ-
line should not be crossed [9]. A similar stance was taken 
by the UNESCO International Bioethics Committee 
(IBC) in October 2015 [10]. The IBC is a permanent 
UNESCO body composed of 36 independent experts 
in the life sciences and humanities. It was established 
in 1993 and it is a global forum for in-depth reflec-
tion in bioethics. The Committee produces advisory 
documents and recommendations on specific bioethical 
issues which are then disseminated and transmitted to 
the Member States and the UNESCO Executive Board, 
but have no binding power on Member States.
However, it is not the case that editing the human 
germline is seen universally as a line that should not be 
crossed, as Collins, Lander and the IBC seem to pur-
port. As a matter of fact, reactions to the application on 
human embryos of CRISPR varied significantly. In the 
UK, for example, where research on human embryos is 
allowed up to 14 days within the remit of the Human 
Embryology Act (see CRISPR & the regulation of 
embryo research in the UK: not a significant break 
with the past), British scientist, Lovell Badge stepped 
in to pronounce a statement against the moratorium:
“I disagree with such a moratorium, which is in 
any case unlikely to be effective. I am fully supportive 
of research being carried out on early human embryos 
in vitro, especially on embryos that are not required for 
reproduction and would otherwise be discarded. If the 
techniques work, there are many interesting questions 
that could be asked about the role of specific genes in 
early human embryo development” [11].
Voices from the British bioethics community also 
lined up to support the experiments. In June 2015, 
Oxford bioethicists Julian Savulescu, Jonathan Pugh, 
Thomas Douglas and Christopher Gyngell were the 
first to clearly position themselves in favor of CRISPR 
applications to embryo research. They published a 
perspective piece in the journal, Protein Cell (to note, 
the same journal where the Chinese team published 
their article), where they argued that research applying 
CRISPR technology to the human embryos:
“Far from being wrong … is a ‘moral imperative’ and 
that, “gene editing could significantly lower this disease 
burden thereby benefiting billions of people around the 
world over time. To intentionally refrain from engaging 
in life-saving research is to be morally responsible for the 
foreseeable, avoidable deaths of those who could have 
benefitted. Research into gene-editing is not an option, it 
is a moral necessity” [12].
Similarly, prominent British philosopher John Harris 
argued that risks to alter future generations (and, possi-
bly, to harm them) are not specific to CRISPR technol-
ogy but are intrinsic in any new reproductive technology 
(including, natural reproduction), and that the ethical 
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challenges raised by the use of CRISPR on human 
embryos had been overemphasized [13,14]. Harris con-
cluded by flipping the argument on its head and arguing 
that safety issues should be understood as an argument 
in favor of doing further research, not of on banning 
it. Harris is also a member of the The Hinxton Group, 
an international research group created to address ethi-
cal and social issues concerning stem cells research and 
embryo research regulations. In a 2015 statement, the 
steering committee of The Hinxton Group defended 
the importance of going forward with basic research on 
human embryos (i.e., in vitro), while putting on hold 
clinical applications of CRISPR on human embryos [15].
Both Harris and Savulescu adopt a utilitarian 
approach to bioethics, according to which the crite-
rion of right action is the principle of utility, and an 
action is morally right if it maximizes utility. Failing to 
continue research that could possibly be lifesaving is, 
from a utilitarian perspective, equal to killing people. 
According to the utilitarian standpoint, acts and omis-
sions are morally equivalent, hence there is no morally 
relevant difference between killing and letting die [16]. 
Following this line of argument, it becomes evident 
why both so strenuously defend going forward with 
research using CRISPR on human embryos.
Precautionary positions toward CRISPR are based 
on two elements: the age-old fear of creating ‘designer 
babies’ or of the return of past eugenics; and the risk 
of unforeseen effects on future generations. These two 
worries express rather different underlying concerns, 
whereas the former is driven by the so-called ‘slippery 
slope argument’ that sounds familiar to philosophers 
and bioethicists alike [17], the latter is an instance of pre-
cautionary considerations driven by limits of knowledge 
and technical feasibility. According to the slippery slope 
argument, allowing a practice X although not particu-
larly ethically troubling it itself (in this instance, allow-
ing the use of gene-editing tools on human embryos 
in vitro) would initiate a process leading to unethical 
practices W, Y, Z (for instance, germline modifications 
of embryos for clinical applications). Albeit widely 
criticized in the philosophical arena [18–20], slippery 
slope arguments are very often used in debates on 
reproductive technologies and in policy making.
CRISPR & the regulation of embryo research 
in the UK: not a significant break with 
the past
In September 2015, Dr Kathy Niakan, group leader 
at Francis Crick Institute (interestingly to note – the 
Francis Crick is a new molecular biology research 
center funded by six UK research institutions, which 
was not yet operational at the time of the application, 
and will be inaugurated in November 2016) in London, 
put forward the first application to the Human Fer-
tilisation & Embryology Authority (HFEA) to carry 
out research using CRISPR on human embryos [21]. 
In the UK, CRISPR research on human embryos falls 
within the remit of the 1990 Human Embryology & 
Fertility Act, which allows research in vitro up to 14 
days. Clinical applications – in other words, transfer to 
uterus of the embryos, are prohibited by law [22]. The 
HFEA oversees assisted reproduction (in vitro fertiliza-
tion [IVF] and related practices such as preimplanta-
tion genetic diagnosis, as all clinics performing assisted 
reproduction services need to have been granted a 
license from the HFEA) and research on human 
embryos, which are supernumerary from IVF [22]. For 
research on human embryos to be permitted, a specific 
HFEA license needs to be granted outlining the details 
of the research project [22].
Positioning CRISPR research on human embryos 
within the context of the UK regulatory framework 
for embryo research is important to understand the 
social and political context that has fostered the sup-
port to CRISPR research in the UK. The 14-day 
limit for conducting research on human embryos 
came about as a result of the IVF Inquiry, which was 
established in 1982 following the birth of the first 
‘test tube’ baby (IVF baby), Louise Brown, in 1978. 
Reflecting on this limit had become an urgent matter 
to address as IVF necessarily entails the creation of 
supernumerary embryos – that is, embryos that are 
not implanted in utero and whose further use (if any) 
needed to be decided. The committee, led by philoso-
pher Mary Warnock, was established in 1982 with 
the task of developing a time limit for research on 
human embryos [23]. Mary Warnock’s understanding 
of her role as chair of the committee was to reach an 
acceptable compromise between opposing views, a 
compromised based on a deliberative process. In the 
case of regulating research on human embryos, these 
incompatible moral premises would see at one end of 
the spectrum those who assumed a ‘sanctity of life’ 
position, and at the other end those who adopted a 
more utilitarian oriented perspective. Developmental 
biologist Anne McLaren was called in to provide her 
expertise to the committee in search for a compro-
mise between the two opposed positions [23]. Anne 
McLaren recommended to limit research on human 
embryos to the 14th day of development as this 
marks the emergence of the primitive streak in the 
human embryo, which in turn signals the beginning 
of gastrulation – that is the first differentiation of the 
embryonic inner cell mass into three layers – endo-
derm, mesoderm and ectoderm – a third of which will 
later develop into the nervous system. Gastrulation 
also corresponds to the last point in embryonic devel-
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opment in which the embryo could cleave to twins. 
Hence the emergence of the primitive streak was 
framed as the beginning of individual development 
and the term ‘pre-embryo’ was coined to describe the 
pre 14-day embryo [23]. The Warnock report recom-
mendation was enshrined into law in 1990, in what 
became the Human Fertilisation and Embryology 
Act, which led to the establishment of the HFEA.
In February 2016, the HFEA granted approval to 
Kathy Niakan’s request [24]. The minutes of the deci-
sion (which are fully available here [25]) clearly indi-
cate that the research project delineated by Niakan 
did not involve any clinical applications of the 
gene-edited embryos or gene-edited-derived human 
embryonic stem cells, nor involved researching for a 
time period longer than 14 days, thus falling squarely 
within the limit of the British law. The approval is 
conditional to the approval of the Institute’s research 
ethics committee (see above) [25].
It will now be evident how in the UK CRISPR 
genome-editing technology applied on the human 
embryos represents only the latest type of technology 
to do research on embryos in vitro, rather than a sig-
nificant break with the past. This is why the two main 
arguments outlined above against the use of CRISPR 
on human embryos were almost absent from the UK 
debate, with the exception of those who adopt a sanc-
tity of life position and are against in toto to the use of 
human embryos for research [26].
As a matter of fact, Julian Hitchcock, a British 
lawyer specialized in the regulation of emerging life 
science technologies, commented that:
“CRISPR-Cas9 is of obvious utility to any of the 
‘principal purposes’ listed by the Human Fertilisation & 
Embryology Act, so the decision of the Human Fertilisa-
tion & Embryology Authority to permit it should never 
have been in doubt: Niakan might as well have applied 
to use a new sort of test tube” [27].
CRISPR applications beyond the human 
embryo
In this section we outline applications of CRISPR 
gene-editing technologies that have been to some 
extent overshadowed by the main focus of debate on 
CRISPPR applications to human embryos (with some 
notable early exceptions [28–31]). They involve respec-
tively the use of CRISPR to eradicate disease vectors; to 
create humanized animal models for organ transplant; 
and to genetically engineer crops.
CRISPR to eradicate disease vectors
Endonuclease genes such as Cas9 (or other Cas-related 
proteins) cut the corresponding chromosomal locus 
lacking them. This in turn induces the cell to repair 
the break by copying the nuclease (enzyme) gene onto 
the damaged chromosome via homologous recombi-
nation [32]. This mechanism, called ‘gene drive’ was 
developed in Drosophila melanogaster (i.e., the com-
mon fruit fly used ubiquitously as an animal model in 
molecular genetics laboratories worldwide) but is now 
being applied to other species such as Aedes aegypti, the 
carrier for dengue fever as well as Zika virus, to engi-
neer the mosquitoes so that they produce only male off-
spring (that do not bite) [33]. When an organism carry-
ing an engineered endonuclease gene drive mates with 
a wild-type organism, the gene drive is preferentially 
inherited by all offspring. This can enable the drive to 
spread until it is present in all members of the popula-
tion. If the gene in question is propagated across mul-
tiple generations, the mosquitoes would eventually go 
extinct (pending acquiring of resistance) [32,33]. Drive-
mediated genome alterations are not permanent on an 
evolutionary timescale, and would not be effective in 
species that reproduce asexually, with slow reproduc-
tive cycles or with closed reproductive niches. Hastings 
Center bioethicist, Gregory Kaebnick notes that “evo-
lutionary processes would hardly be nullified by gene 
drives,” as the acquisition of resistance to gene drives 
is not a matter of ‘if ’, but of ‘when’. However, he adds 
that, “Still, the basic point is rather shocking from an 
environmentalist’s perspective: gene drives hold out the 
prospect of altering species in a way we have not been 
able to do before” [34].
Genetically engineered mosquitoes of the A. aegypti 
species have been developed by Oxitec – a British 
company purchased by the US synthetic biology com-
pany, Intrexon – and have already been released in 
the Piracicaba district in Brazil in 2015, with results 
indicating a reduction in wild mosquito larvae of 
82% by the end of the year [35]. On 18 January 2016, 
the Brazilian city of Piracicaba has announced that it 
will expand the use of genetically modified mosqui-
toes to fight A. aegypti and the spread of Zika. In May 
2016, the same company, Oxitec, announced that 
CRISPR-engineered mosquitoes would be released 
to the Cayman Islands to combat the spread of den-
gue, Zika and chikungunya (another type of tropi-
cal fever) [36]. The US FDA is currently considering 
an investigational trial for Oxitec solutions in the 
Florida keys, where cases of Zika have been recorded 
since July 2016, which if approved, would be the first 
application of CRISPR-engineered mosquitoes in the 
USA [37].
To control the unpredictable consequences on the 
ecosystem, scientists have proposed that a reverse 
engineering system could be built in the engineered 
species as a way of providing ‘intrinsic safeguards’ if 
the original drive system fails to perform as desired. 
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Methods of confining gene-drive systems to local 
populations are also being explored including ‘daisy 
gene-drive systems’, which may be ‘powerful enough 
to eliminate all copies of an unwanted global drive 
system via local immunizing reversal or population 
suppression before disappearing themselves’ [38]. 
Applications to the control of invasive species through 
gene drive have also been envisaged, as gene-drive 
applications to improve the sustainability and safety 
of pesticides and herbicides [33].
While the aforementioned applications are all 
examples of ‘well-meant’ applications of gene drive, 
it is not implausible to imagine that the same tech-
nology could also be used for the opposite purposes 
of releasing in the environment disease-carriers engi-
neered mosquitoes. Hence, CRISPR in this context 
represents a perfect instance of a dual-use dilemma 
of research whose ethical implications demand 
to be considered [39,40].
The ‘disruption of natural order’ is an example 
of a classic bioconservative worry. According to this 
view, ‘tampering’ or ‘meddling’ with nature is intrin-
sically wrong regardless of the consequences [41,42]. 
‘Nature’ is assumed to hold an intrinsic moral value 
as the product of an intelligent design. We think, 
in line with others [43,44], that the ‘natural’ should 
not hold an intrinsic moral value. However, we think 
that the bioconservatives’ concerns should not be too 
quickly dismissed. The value of the argument lies 
not, in our opinion, on the sacrality of the natural 
order, but on another consideration: a genetic trait 
that may be deleterious in one context (e.g., thalas-
semia) and for the individual may turn out to be 
advantageous in another context (e.g., resistance to 
malaria). At the same time, what counts as normal 
is context dependent [45]. Along similar lines, Robin 
Lovell-Badge has pointed out, for example, that one 
of the applications of CRISPR in the context of 
embryo editing could be to delete the allele APOE4, 
which is the allele of the apolipoprotein E associ-
ated with Alzheimer’s disease (with heterozygotes 
being approximately three-times and homozygotes 
15-times more likely to develop the disease than 
homozygotes). However, Robin Lovell-Badge notes 
that, “with any risk allele, particularly a common 
one, it is important to ask why it is maintained in 
the population at a relatively high frequency, could 
APOE4 in fact confer some advantage to carriers 
unrelated to its connection to Alzheimer’s?” [46]. 
There are very tangible risks – which are very dif-
ficult to predict – in deleting genetic diversity as we 
may end up deleting traits that can turn out advan-
tageous in a different context, or advantageous for 
the species although, not for the individual.
CRISPR applied to humanized animal models 
for organ transplant
The shortage of organs for human transplants is one 
of the longstanding unresolved medical problems 
worldwide. Ethical dilemmas arise when having to 
develop criteria for the allocation of a scarce resource. 
An increasing number of scholars are now portray-
ing CRISPR technology as a way out of the shortage 
through the development of humanized animal mod-
els for organ transplant [47–50]. Human genes can be 
inserted into non-human animals (with pigs appear-
ing as the most promising candidates) at the stage of 
blastocyst. Humanized animal models could then 
be developed from chimeric blastocysts, from which 
organs for human transplant could be harvested. 
Thanks to the human-inserted genes, such organs 
would not cause the problem of graft-versus-host 
disease, which leads to the transplanted organ being 
rejected by the host (and hence to organ failure and 
possible death of the host). This is not science fic-
tion, although Margaret Atwood, in her book, Oryx 
and Crake, had anticipated this scenario in 2003. 
In early August 2016, the NIH announced plans 
to lift the moratorium – which was put in place in 
September 2015, before any funding of the kind had 
actually been issued – on human–animal chimera 
research and engaged in a heightened review of the 
research [51,52]. According to Inso Hyun, Associate 
Professor of Bioethics & Philosophy at Case Western 
University, who has written an op-ed in PLoS Biol-
ogy, “It is easy to overstate the concern about the 
moral humanization of acute human/nonhuman 
chimeras” [50].
Hyun’s type of reasoning falls along the well-estab-
lished lines of beneficence-based arguments, which are 
the main arguments in support of carrying out this 
type of research. Indeed, writes Hyun: “Given the 
noble aims of this research, it is puzzling to some why 
the NIH is so nervous about providing federal funds 
to researchers with a track record of success in this 
area” (page 1) and adds figures to point out the current 
shortage of human organs for transplantation in the 
USA, and what this research would do to solve this. In 
general, beneficence-based arguments are structured as 
follows: if humanized animal models for organ trans-
plant can be the solution to the longstanding problem 
of shortage of organs, then we have strong beneficence 
reasons to go forward. The argument from beneficence 
and the moral imperative to relieve suffering are often 
used to support scientific advances in the face of pos-
sible public resistance and disagreement. However, we 
believe that concerns about human–animal chimeras 
should not be dismissed too quickly, in a similar way to 
concerns about releasing gene-drive engineered mos-
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quitoes in the ecosystem. The value of the concerns 
lies, once again, not in a supposed sacrality of human 
nature, which would be supposedly corroded by the 
animal genes – in this, we agree with Hyun – but 
in an open discussion about resource allocation and 
prioritization untouched by Hyun. To put it simply, 
we should seriously consider if and why we cannot 
address the problem of shortage of human organs in 
another way which does not lead to human–animal 
chimeras, for example, through changes in our opt-in 
policies to donate organs and facilitate ways to make 
that possible. We should be wary of arguments that 
appeal uncritically to an ‘apparent and urgent’ and 
‘the humanitarian importance’ of research (page 2). 
Nothing is apparent or urgent; we always need to care-
fully consider alternatives, and in the case of organs for 
human transplants, there are alternatives.
In addition, cross-species experiments raise other 
longstanding discussions concerning the moral sta-
tus of non-human animals and their use in research 
for the benefit for our species [53–55], and the deriva-
tion of chimeric and hybrid human embryonic stem 
cells [56–58]. These are not new ethical issues but need 
to be addressed de novo given the technical feasibility 
allowed by CRISPR of growing humanized organs in 
nonhuman animals.
CRISPR applications in agriculture: does it still 
count as genetically modified organisms?
CRISPR technologies have far-reaching applications 
in agriculture [59]. While transgenic crops have existed 
for years, there are important regulatory questions 
that need to be answered, and social and ethical issues 
around genetically modified organisms for food con-
sumption ‘crop up’ again (pun intended). In April 
2016, the company, DuPont Pioneer, announced 
plans to market CRISPR-modified corn, soybeans, 
canola, rice and wheat. The engineered crops will 
have drought resistance and higher yields [60]. The 
US Department of Agriculture shortly thereafter 
announced that it does not consider the CRISPR corn 
“as regulated by USDA Biotechnology Regulatory 
Services.” Why is that so? As noted by Caplan et al., 
“What makes CRISPR different from other methods 
of agricultural genetic engineering is that it no lon-
ger requires the insertion of foreign DNA into the 
plant genome using a virus, bacterial plasmid or other 
vector system” [40]. In other words, CRISPR-edited 
organisms would no longer classify as transgenic 
organisms in sensu stricto as there is no insertion of 
foreign DNA [61]. The same issue is being debated in 
Europe too, where historically there has been a higher 
opposition to transgenic crops. In Sweden, authorities 
recently said that CRISPR-edited plants should not 
be defined a genetically modified organisms (GMO) 
under EU legislation.
Introducing a new powerful technique in a con-
tested and arguably lagging legal framework might 
prove to be irresponsible and further endanger public 
trust in expert knowledge in a context where this is 
already low. The European Commission was expected 
to give guidance on what products of genome editing 
would be classed as GMOs by the end of 2015, but in 
March 2016 an EC spokesperson commented that the 
“outcome and timeline cannot be pre-empted for the 
time being.” This creates a climate of uncertainty that, 
according to Huw Jones, member of the GMO panel 
European Food Safety Authority, and many others in 
the business who share his view, stifles innovation [62].
The report on genetically engineered crops published 
in May 2016 by the US National Academy of Sciences 
advisory group provides an example of the unsettled eth-
ical issues at stake. According to the report, there is no 
‘substantiated’ evidence that genetically engineered crops 
might be dangerous for human health and damaging for 
the environment. In spite of this, the controversy about 
GMOs remains as it reaches beyond health concerns to 
issues of public trust in expert knowledge. The assump-
tion often made that a knowledge deficit from the part 
of the public (the so-called ‘public deficit model’) [63] 
underlies the public resistance to GMO has been dis-
mantled by many science and technology scholars over 
the past 20 years [64–68]. This needs to be acknowledged 
by policy makers if progress in this area is to be made. 
Public trust in expert knowledge is possibly at historical 
lows in the western world (with resistance to vaccination, 
climate change, evolution, just to name a few). Social 
scientists and bioethicists need to work together to seri-
ously consider the underlying causes of resistance to sci-
ence, which cannot be fixed by a presumption that the 
public needs more information. A responsible approach 
to the use of CRISPR for GMOs and gene drive needs to 
bring together biology and ecology. As put by American 
science and technology scholar, Emma Frow, “it is not 
about the ethical issues of the technology that we need 
to decide, it is about which ‘collective futures’ we want 
to shape for our society, and planet, with CRISPR” [69].
CRISPR embryo debate: momentum building 
outside the USA?
The international controversy on CRISPR research 
on human embryos is far from being settled. In April 
2016, a second paper by Chinese scientists, led by Fan, 
using CRISPR in human embryos was published in 
the Journal for Assisted Reproduction and Genetics [70]. 
To note, this is a different research group from the first 
one who published in Protein & Cell in 2015: the former 
researchers are based at Sun Yat-sen University, whereas 
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the latter are based at Guangzhou Medical University. 
The authors successfully introduced a naturally occur-
ring allele, which is aimed at conferring HIV resistance, 
into early human tripronuclear (nonviable) zygotes 
by CRISPR-mediated genome editing. The modified 
embryos displayed mosaicism in which wild-type cells 
and genetically modified cells coexisted. It should be 
noted that tripronuclear zygotes were the same choice 
of biological model as the one made by the group led 
by Huang et al. in 2015 [4]. It can be argued that the 
choice of using tripronuclear zygotes by both Chinese 
research groups was an explicit strategy to pre-empt crit-
icism by the international community for working on 
human embryos.
Meanwhile, other researchers in Europe have 
announced they plan to apply CRISPR technology 
on human embryos. One example is Frederick Lan-
ner, group leader at Karolinska Institute in Sweden, 
who in an interview with the journal Nature in April 
2016 [71] discussed his plans – approved by his home 
institution – to genetically engineer human embryos 
in order to understand the biology of preimplantation 
development building on his previous work [72], which 
is a goal not dissimilar from Niakan’s research project. 
A government bioethics panel in Japan also recently 
gave the green light to basic research in vitro on human 
embryos, but not to clinical applications, mirroring the 
HFEA regulation of embryo research in the UK [73].
It seems therefore that (at the time of finalizing this 
article, September 2016) there is a building momentum 
on research on human embryos outside the USA. This 
momentum is echoed by recent experiments conducted 
by two teams of scientists, one based at Rockefeller Uni-
versity in the USA and the other at the Wellcome Trust 
Stem Cell Institute and The Gurdon Institute in Cam-
bridge in the UK. These experiments, published in two 
separate articles – Nature and Nature Cell Biology – in 
May 2016 demonstrated for the first time that embryos 
can be cultured in vitro for 12–14 days [74,75]. Prior to 
these findings, scientists were able to culture embryos 
in vitro until the 9th day. Early reactions from both 
scientists and bioethicists to these experiments have 
been favorable and enthusiastic both in the UK and in 
the USA, with some exceptions from scholars who are 
outright against using embryos for research [29,76]. Brit-
ish bioethicist, John Harris, already quoted above, has 
taken a clear position in favor of redrawing the 14-day 
rule. According to Harris, whereas previously there was 
no need or reason to revise (i.e., extend) the limit, the 
fact that embryos can now be cultured in vitro beyond 
the 14th day makes the case for a change in the law, on 
the basis of the expected benefits that this research could 
bring to humanity [77]. Along similar lines, the director 
of germline and epigenomic research at The Gurdon 
Institute in Cambridge, UK, Azim Surani, maintained 
before these recent findings emerged that there was a 
strong case for extending the time frame for research on 
human embryos beyond 14 days in light of the expected 
benefits of research and the scarce knowledge of early 
embryo development in humans [78].
In contrast to the regulation of embryo research in 
the UK, in the USA there is no equivalent of a cen-
tral regulatory body such as the HFEA. In the USA, 
the Director of the NIH, and the President of the 
USA have the discretion to prohibit federal funding 
to research that they do not approve (as was formerly 
the case with President Bush and research on human 
embryonic stem cells) [79]. This does not mean that 
private funds cannot be invested in research, although 
the burden of justification and persuading investors, 
is on the privately funded laboratories. For example, 
in California the Institute for Regenerative Medicine 
announced that they will finance research on CRISPR 
on human embryos [80]. Dr Eli Adashi, former Dean of 
Medicine and Biological Sciences at Brown University, 
recently argued that cultural differences play a role in 
the formulation of science policies, and that “the diver-
gent outlooks of the United Kingdom and the United 
States on human embryo research [are] informed by 
dissimilar positions across the prochoice/prolife divide. 
These distinctions are very much in evidence in the 
regulatory arena” [79]. While the UK seems to be char-
acterized by a ‘compromise-seeking’ attitude toward 
bioethical controversies (evident in Mary Warnock’s 
IVF Inquiry), the USA seems to be much more polar-
ized at the two extremes. Isasi and Knoppers’ results of 
a survey of policy approaches to embryonic stem cell 
research in 50 countries position the UK at the most 
liberal end of the spectrum [81]. However, the posi-
tion of the UK is less permissive than it seems, as the 
Human Embryology Act does not grant an umbrella 
permission to research on human embryos within the 
14-day limit, but a specific license needs to be granted 
by HFEA to each research group following an applica-
tion, and the license is a conditional approval which 
needs to be followed by the approval by a research 
ethics committee.
It should be made absolutely clear that a revision 
of the 14-day limit for research on human embryos in 
the UK would entail a parliamentary vote and HFEA 
approval to change the Human Fertilisation & 
Embryology Act. As explained in a section “CRISPR 
and the regulation of embryo research in the UK: 
not a significant break with the past,” the 14-day 
limit was put in place on the basis of biological and 
philosophical considerations, with the aim to find a 
workable solution in the face of moral disagreement 
on the status of the human embryo, and not due to 
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technical limits alone. If scientists are now able to 
grow the embryos in vitro for longer than 14 days, it 
does not necessarily entail that they ought to do it. 
This line of reasoning is precisely what 17th century 
philosopher, David Hume condemned as an ‘incon-
ceivable’ deduction of what one ought to do from a 
set of is-premises – in other words, from what one 
can do. In other words, Hume argued that no ethi-
cal conclusion, for example, “we ought to extend the 
14-day limit for embryo research,” can be inferred 
from purely factual premises, such as, “scientists are 
able to grow embryos in vitro for >14 days.” A change 
in the law cannot rest solely on technical feasibility 
grounds. In addition,the potential benefits of extend-
ing the limit beyond 14 days should not be uncritically 
accepted on the basis of scientists’ assumptions (for a 
critique in relation to CRISPR-editing technology, 
see Jasanoff et al., 2016) [82].
Conclusion
In this paper we have provided an overview of the inter-
national CRISPR bioethics debate as it has unfolded 
since the publication in April 2015 of the first research 
paper by Huang et al. [4] of the applications of CRISPR 
technology in human embryos. As we are bioethi-
cists working in the UK, we have contextualized the 
discussion on the application to human embryos of 
CRISPR within the British regulatory system. We have 
commented on the support that CRISPR research on 
human embryos has received in the UK, and argued 
that this support needs to be understood within the 
British sociopolitical context of embryo research since 
the establishment of the HFEA in 1990, where it does 
not represent a discontinuity with the past. We have 
also discussed the recent experiments that have demon-
strated the technical feasibility of cultivating embryos in 
vitro for up to 14 days, and possibly beyond this limit. 
We do not believe that technical feasibility alone should 
drive a change in the law. In the central part of this 
paper we have pointed to some areas that deserve the 
attention of the bioethical community beyond human 
embryos, namely engineering mosquitoes to eradicate 
diseases, engineering animals to harvest organs for 
human transplant and engineering crops. To conclude, 
a critical analysis of pros and cons, which aims to avoid 
standardized patterns of reactions to the emergence of 
new technologies, is necessary to move forward in the 
CRISPR debate and extend it beyond the narrow focus 
on editing the human embryos. An interdisciplinary, 
international task-force that brings together scientists, 
bioethicists, social scientists, lawyers, policy makers and 
lay citizens, and that does not construe the ethical and 
the social issues of CRISPR technologies as ‘lagging 
behind’ the science, should be convened. It is impor-
tant to remember that editing the human embryo with 
CRISPR technology is not the only way in which we 
can change future generations, and certainly not the 
way that would have the greatest impact on our planet.
Future perspective
In spite of optimistic and often hyped previsions and 
of the importance to push forward scientific innova-
tion, it is important to bear in mind that we are dealing 
with uncertainties, and should not take for granted the 
expected benefits of the CRISPR technology. We have 
seen similar arguments unleashed before for nanotech-
nology, synthetic biology, stem cell research and gene 
therapy. We agree with American historian of science 
Ben Hurlbut, who writes, “technological controversies 
have come and gone, but modes of reacting to them 
have come to be patterned and institutionalized” [83], 
while British sociologist Adam Hedgecoe has referred 
to this pattern as the “reinforcement of sociotechnical 
expectations” operated by bioethicists [84].
The debate on CRISPR is no exception in this 
respect. However, we should resist this standard mode 
of bioethics reacting to a new technology, and of poli-
cies ‘lagging behind science’, and be wary of accept-
ing a linear model of innovation that presupposes that 
a new technology will bring about great benefits for 
society. A number of issues remain beyond our knowl-
edge, the first of which is the complex relationship 
between genes and the environment. Intervening in 
human evolution might prove advantageous in a par-
ticular context at present, but not in another context 
in the future. In this sense, CRISPR can teach us some 
humility. It is the task of bioethicists, and social sci-
entists to critically unpack the impacts, benefits, con-
sequences, promises and fears of CRISPR technology.
Editing embryos (and the germ-line) in the context 
of basic research will likely reveal meaningful informa-
tion concerning embryo development, possibly shed-
ding light on the reasons behind early miscarriages and 
infertility, as argued by Niakan and Lanner. However, 
we agree with Lundberg and Novak [85], among others, 
that most of the clinical applications of CRISPR will 
not lie in editing the germline, but in editing somatic 
tissues. It may very well be that CRISPR represents 
the final upheaval of a gene therapy field that has had 
many ups and downs over the past 30 years. Indeed, 
the first gene therapy clinical trial in humans has 
been given the go ahead in China, and a similar one 
is expected to be given go ahead soon in the USA [86]. 
This clinical trial is designed for cancer patients in 
order to improve the success rate of gene therapies and 
to reduce the incidence of relapses. Other gene therapy 
trials may be approved in the near future. CRISPR 
applications to the development of humanized animal 
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models for organ transplant, and the applications of 
CRISPR to eradicate disease vectors and other species 
with gene drive, are in our opinion two major break-
throughs of the technology that represent a disconti-
nuity with the past. They deserve an ethical assessment 
in terms of allocation and prioritization of resources, 
including in terms of beneficence-based arguments 
and risk assessment.
In the context of assisted reproduction, gene editing 
will be used as an alternative preimplantation genetic 
diagnosis (PGD) in IVF for those rare cases in which 
parents homozygous for a lethal mutation (e.g., Hun-
tington disease) want to have biologically related chil-
dren and for which PGD is not an option (as all embryos 
are affected). If implemented in assisted reproduction, 
selected genes of embryos created through IVF will be 
modified with CRISPR in vitro prior to being trans-
ferred in utero. In this context, the question to ask is 
whether the quest for a biologically related child is war-
ranted in the context of allocation of scarce resources, 
and with the existence of alternatives such as PGD that 
provide a viable alternative in most cases. Our soci-
ety needs to discuss the meaning of biological kinship 
in light of the available alternatives, such as adoption. 
We need to ask ourselves: should we not invest more 
resources in making adoption possible? The same 
resource allocation questions should be asked in the 
context of creating chimeric animal models for organ 
donation: should we not invest more in facilitating 
ethical human organ donation?
Executive summary
•	 This article explores the ethical issues raised by the application to human embryos of CRISPR Cas/9 from March 
2015 to April 2016.
•	 It shows the necessity of widening the attention beyond the focus on human embryo to other nonhuman 
applications.
Clustered regularly interspaced short palindromic repeats research on human embryos
•	 Clustered regularly interspaced short palindromic repeats (CRISPR) is a ubiquitously used technology in 
laboratories worldwide thanks to its versatility as it is applicable to all eukaryotic cells.
•	 First applied in mammalian cells in 2015, CRISPR became the center of a global debate in April 2015 due to the 
announcement of a group of Chinese scientists that they had applied the technology on human nonviable 
embryos.
•	 Negative reactions to the Chinese announcement came largely from the USA, featured appeals to the 
Precautionary Principle and to slippery slope arguments, and led to a self-imposed moratorium on CRISPR 
research on human embryos.
•	 In the UK, many scientists and ethicists lined up in favor of allowing basic research with CRISPR on human 
embryos.
Positioning CRISPR research within the regulation of embryo research in the UK
•	 In the UK, embryo research is allowed up until the 14th day of development; thus, allowing research with 
CRISPR technology on embryos does not represent a significant breach with the past.
•	 Reactions from the UK can be explained if we position the application of CRISPR to human embryos within the 
regulation on embryo research (Human Embryology Act, 1990).
CRISPR applications beyond the human embryo
•	 There are a number of current and possible future applications of CRISPR gene-editing technologies that do 
not involve the human embryo and deserve ethical attention. These include:
 – Gene drive to genetically engineered mosquitoes to eradicate disease vectors. Ethical issues: effects on 
ecosystem, altering biodiversity, dual use of research.
 – CRISPR to create humanized animal models for human organ transplant. Ethical issues: cross-species 
experiments, allocation and prioritization of resources toward creation of chimeric animal models for 
organ transplants instead of implementing policies to facilitate organ donation from humans to humans.
 – CRISPR to genetically engineer crops. Ethical issues: Uncertainty in terms of regulation as genetically 
modified crops may not count as GMOs.
CRISPR research on human embryos: momentum building outside the USA?
•	 The debate on CRISPR has not been settled: in this section we present some of the most recent developments 
involving the use of CRISPR on human somatic cells and the present state of the debate on embryo research. 
Other countries such as Sweden and Japan are going forward with CRISPR applications on human embryos.
Future perspective
•	 Therapeutic potential of CRISPR lies in applications to somatic cells (gene therapy) rather than in germline 
cells.
•	 In the context of assisted reproduction preimplantation genetic diagnosis is a viable alternative to CRISPR 
except in rare cases of dominant genetic conditions, where CRISPR could represent a viable alternative for 
parents who are carriers of the dominant genetic condition and want to have biologically related children.
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